Drug Information

Drug General Information
Drug ID
D0E6SQ
Former ID
DCL001153
Drug Name
ATL1102
Indication Multiple scierosis [ICD9: 340; ICD10:G35] Phase 2 [551049]
Company
ISIS Pharm; Antisense Therapeutics
Target and Pathway
Target(s) mRNA of integrin alpha-4 Target Info Modulator
KEGG Pathway PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Cell adhesion molecules (CAMs)
Hematopoietic cell lineage
Leukocyte transendothelial migration
Intestinal immune network for IgA production
Regulation of actin cytoskeleton
Leishmaniasis
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
PANTHER Pathway Integrin signalling pathway
Pathway Interaction Database Beta1 integrin cell surface interactions
Integrin family cell surface interactions
Arf6 trafficking events
CXCR4-mediated signaling events
Plexin-D1 Signaling
a4b7 Integrin signaling
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
VEGFR3 signaling in lymphatic endothelium
Alpha4 beta1 integrin signaling events
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Integrin cell surface interactions
WikiPathways Focal Adhesion
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
Integrin cell surface interactions
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
References
Ref 551049Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.